MAPT and Alzheimer disease: Evidence thus far highlights that tau, rather than amyloid-beta (Aβ) alone, is a reliable indicator of future clinical progression,11,18 and is well associated with cognitive change in early stages of Alzheimer’s disease.19–23 Therefore, if tau patterns and their progression are indeed heterogenous, it appears likely that tracking tau with a single set of regions across participants may misrepresent a significant portion of them.